Baeza-Hernández Gloria, Cañueto Javier
Department of Dermatology, Complejo Asistencial Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Centro de Investigación del Cáncer (CIC)-CSIC, Laboratory 20, 37008 Salamanca, Spain.
Cancers (Basel). 2023 Dec 28;16(1):158. doi: 10.3390/cancers16010158.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans and has the potential to progress locally, metastasize, and cause death in a subset of patients. cSCC is especially common in the elderly, and it will probably represent a major health concern in the near future. Surgery is the standard treatment for cSCC, but intralesional therapies can sometimes be considered for certain patients and under certain circumstances. The choice of intralesional treatment depends on the patient's characteristics and the clinician's previous experience and expertise. Here we are reviewing intralesional treatments for cSCC and keratoacanthoma (KA). We have started with some classic drugs, such as methotrexate and 5-fluorouracil, bleomycin, interferon, and cryosurgery, but also comment on electrochemotherapy. Finally, we have focused on novel therapies, some of which are under development, and future perspectives, including intralesional immunotherapy and oncolytic viruses.
皮肤鳞状细胞癌（cSCC）是人类第二常见的癌症，有可能在局部进展、转移，并导致一部分患者死亡。cSCC在老年人中尤为常见，在不久的将来可能会成为一个主要的健康问题。手术是cSCC的标准治疗方法，但在某些患者和某些情况下，有时也可以考虑采用瘤内治疗。瘤内治疗的选择取决于患者的特征以及临床医生以前的经验和专业知识。在这里，我们回顾了cSCC和角化棘皮瘤（KA）的瘤内治疗方法。我们首先介绍了一些经典药物，如甲氨蝶呤、5-氟尿嘧啶、博来霉素、干扰素和冷冻手术，同时也对电化学疗法进行了评论。最后，我们重点介绍了一些正在开发的新型疗法以及未来的前景，包括瘤内免疫疗法和溶瘤病毒。
